英夫利昔单抗在IVIG无应答川崎病中的应用研究进展

冯禧炜; 龚方戚

doi:10.12372/jcp.2025.24e1214

临床儿科杂志 >

2025 , Vol. 43 >Issue 11: 878 - 882

DOI: https://doi.org/10.12372/jcp.2025.24e1214

文献综述

英夫利昔单抗在IVIG无应答川崎病中的应用研究进展

冯禧炜 ,
龚方戚

展开

浙江大学医学院附属儿童医院心血管内科（浙江杭州 310000）

龚方戚电子信箱：gongfangqi@zju.edu.cn

收稿日期: 2024-11-14

录用日期: 2025-03-13

网络出版日期: 2025-11-06

收起

Progress on the application of infliximab in IVIG-resistant Kawasaki disease

FENG Xiwei ,
GONG Fangqi

Expand

Department of Cardiology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China

Received date: 2024-11-14

Accepted date: 2025-03-13

Online published: 2025-11-06

Fold

摘要

本综述旨在系统探讨英夫利昔单抗（infliximab）在静脉注射免疫球蛋白（IVIG）无应答川崎病（KD）患者中的应用价值，围绕其作用机制、临床疗效与安全性展开分析，并结合国内外最新研究进展，综合评估该药物的治疗效果与局限性。结果表明，英夫利昔单抗可有效缩短退热时间，降低炎症标志物水平，同时减少冠状动脉病变的发生率。随着对 KD 病因及发病机制研究的不断深入，英夫利昔单抗有望成为 IVIG 无应答 KD 患者的重要治疗选择，为优化 KD 临床诊疗策略、改善患者长期预后提供新的思路与指导。

关键词： 英夫利昔单抗; 静脉注射免疫球蛋白; 川崎病; 临床疗效; 儿童

本文引用格式

冯禧炜 , 龚方戚 . 英夫利昔单抗在IVIG无应答川崎病中的应用研究进展[J]. 临床儿科杂志, 2025 , 43(11) : 878 -882 . DOI: 10.12372/jcp.2025.24e1214

Abstract

This review aims to systematically evaluate the therapeutic role of infliximab in patients with Kawasaki disease (KD) who are resistant to intravenous immunoglobulin (IVIG), with a focus on its mechanism of action, clinical efficacy, and safety profile. By synthesizing recent advances in both domestic and international research, we provide a comprehensive assessment of the benefits and current limitations of infliximab therapy. Evidence indicates that infliximab significantly shortens fever duration, reduces levels of inflammatory biomarkers, and lowers the risk of coronary artery lesions. As understanding of the etiology and immunopathogenesis of KD continues to evolve, infliximab is emerging as a promising therapeutic option for IVIG-resistant cases. This review highlights its potential to inform optimized clinical management strategies and improve long-term outcomes in affected patients.

Key words： infliximab; intravenous immunoglobulin; Kawasaki disease; clinical efficacy; child

参考文献

[1]	Newburger JW, Takahashi M, Burns JC. Kawasaki disease[J]. J Am Coll Cardanol, 2016, 67(14): 1738-1749.
[2]	Burns JC. The etiologies of Kawasaki disease[J]. J Clin Invest, 2024, 134(5): e176938.
[3]	Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies[J]. Expert Rev Clin Immunol, 2017, 13(3): 247-258.
[4]	McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999.
[5]	Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial[J]. Lancet, 2014, 383(9930): 1731-1738.
[6]	Chen J, Liao J, Xiang L et al. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review[J]. Front Immunol, 2023, 14: 1237670.
[7]	Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial[J]. Lancet Child Adolesc Health, 2021, 5(12): 852-861.
[8]	Wang L, He M, Wang W, et al. Efficacy and safety of infliximab in the treatment of Kawasaki disease: a systematic review and meta-analysis[J]. Eur J Pediatr, 2024, 183(4):1765-1776.
[9]	Cole LD, Osborne CM, Silveira LJ, et al. IVIG compared with IVIG plus infliximab in multisystem inflammatory syndrome in children[J]. Pediatrics, 2021, 148(6): e2021052702.
[10]	Miura M, Kobayashi T, Igarashi T, et al. Real-world safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease: a postmarketing surveillance in Japan (SAKURA Study)[J]. Pediatr Infect Dis J, 2020, 39(1): 41-47.
[11]	Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease[J]. Pharmacogenomics J, 2013, 13(1):52-59.
[12]	董明星, 王喜霞, 焦富勇, 等. 川崎病基因多态性的研究进展[J]. 中国当代儿科杂志, 2023, 25(12): 1234-1238.
	Dong MX, Wang XX, Jiao FY, et al. Research advances in genetic polymorphisms in Kawasaki disease[J]. Zhongguo Dangdai Erke Zazhi, 2023, 25(12): 1234-1238.
[13]	Ye Q, Gong FQ, Shang SQ, et al. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8⁺T cell activation in Kawasaki disease[J]. Clin Immunol, 2016, 171(10): 25-31.
[14]	胡珊, 王永清. 川崎病外周血淋巴细胞与T细胞亚群的相关性分析[J]. 当代医学, 2015, 21(29): 1-3.
	Hu S, Wang YQ. Correlation analysis of peripheral blood lymphocytes and T cell subsets in Kawasaki disease[J]. Dangdai Yixue, 2015, 21(29): 1-3.
[15]	Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models[J]. Nat Rev Rheumatol, 16(7): 391-405
[16]	Ohnishi Y, Okada S, Kawakami-Miyake A, et al. Safety and feasibility of infliximab therapy in children with Kawasaki disease who received live vaccinations[J]. Pediatr Infect Dis J, 2022, 41(9): e388-e392.
[17]	Alexander H. Sprague, Raouf A. Inflammatory cytokines in vascular dysfunction and vascular disease[J]. Biochem Pharmacol, 2009, 78(6): 539-552
[18]	Hachiya A, Kobayashi N, Matsuzaki S, et al. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients[J]. Clin Rheumatol, 2018, 37(7):1937-1943.
[19]	Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children[J]. Cochrane Database Syst Rev, 2017, 1(1): CD011188.
[20]	Li D, Li X, Dou W, et al. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis[J]. Transl Pediatr, 2021, 10(5): 1294-1306.
[21]	宋木雯. 英夫利昔单抗治疗IVIG无反应型川崎病的META分析[D]. 重庆医科大学, 2020.
	Song MW. Meta-analysis of infliximab treatment for IVIG-resistant Kawasaki disease[D]. Chongqing Medical University, 2020.
[22]	彭宇, 刘小惠, 欧阳倩, 等. 免疫球蛋白无应答川崎病再次免疫球蛋白/英夫利昔单抗和激素治疗队列研究[J]. 中国循证儿科杂志, 2022, 17(1): 35-38.
	Peng Y, Liu XH, Ouyang Q, et al. Treatment of refractory Kawasaki disease with IVIG, infliximab or corticosteroids: a cohort study[J]. Zhongguo Xunzheng Erke Zazhi, 2022, 17(1): 35-38.
[23]	颜凯, 林平, 尧战勇. 英夫利昔单抗联合阿托伐他汀治疗川崎病效果及对患儿血清NT-proBNP、iNOS影响[J]. 临床误诊误治, 2022, 35(3): 36-39.
	Yan K, Lin P, Yao ZY. Efficacy of infliximab combined with atorvastatin in the treatment of Kawasaki disease and its effects on serum NT-proBNP and iNOS in children[J]. Linchuang Wuzhen Wuzhi, 2022, 35(3): 36-39.
[24]	Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review[J]. J Crohns Colitis, 2015, 9(9): 806-815.
[25]	Antonio JR, Sanmiguel J, Cagnon GV, et al. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients[J]. An Bras Dermatol, 2016, 91(3): 306-310.
[26]	Sapountzi E, Fidani L, Giannopoulos A, et al. Association of genetic polymorphisms in Kawasaki disease with the response to intravenous immunoglobulin therapy[J]. Pediatr Cardiol, 2023, 44(1): 1-12.
[27]	黄敏. 单细胞测序技术在川崎病研究中的应用现状[J]. 临床儿科杂志, 2023, 41(7): 481-485.
	Huang M. Application of single cell sequencing technology in Kawasaki disease research[J]. Linchuang Erke Zazhi, 2023, 41(7): 481-485.
[28]	Rahman P, Baer P, Keystone E, et al. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry[J]. BMC Rheumatol, 2020, 4: 46.
[29]	Xie LP, Zhao L, Chu C, et al. Retrospective analysis of infliximab in the treatment of Kawasaki disease[J]. Zhonghua Erke Zazhi, 2022, 60(1): 14-19.
[30]	Masuda H, Kobayashi T, Hachiya A, et al. Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan[J]. J Pediatr, 2018, 195: 115-120.
[31]	Hur G, Song MS, Sohn S, et al. Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea[J]. Korean Circ J, 2019, 49(2): 183-191.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献